Through a trust, Dudum sold about $33.4 million worth of his company’s stock on Thursday, according to a filing with the ...

The U.S. Federal Trade Commission is probing complaints about telehealth platform Hims & Hers regarding its advertising and ...

Hims & Hers Health (NYSE:HIMS) stock fell 4.1% in after-hours trading on Thursday following a Bloomberg report that revealed ...

At $13.6 billion in market capitalization, Hims & Hers stock costs a pricey 70 times trailing earnings. It's even more ...

Hims & Hers has been an incredible stock to own over the last few years, making shareholders rich. It has $2 billion in ...

Insider moves in IonQ, Hims and Hers, Eli Lilly, and TransMedics reveal bold buys, record sales, and signals worth watching.

The healthcare company is experiencing excellent sales growth, but investors are concerned about its longer-term prospects.

Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong ...

Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending ...

And it raised questions about Hims & Hers' business practices. Here's what you need to know about these recent developments and whether you should be thinking twice about buying Hims & Hers stock.

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Hims & Hers Health (NYSE:HIMS) stock fell 5% in after-hours trading on Thursday following a Bloomberg report that revealed the Federal Trade Commission has been investigating the telehealth company’s ...